Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 123

1.

Using chimeric mice with humanized livers to predict human drug metabolism and a drug-drug interaction.

Nishimura T, Hu Y, Wu M, Pham E, Suemizu H, Elazar M, Liu M, Idilman R, Yurdaydin C, Angus P, Stedman C, Murphy B, Glenn J, Nakamura M, Nomura T, Chen Y, Zheng M, Fitch WL, Peltz G.

J Pharmacol Exp Ther. 2013 Feb;344(2):388-96. doi: 10.1124/jpet.112.198697. Epub 2012 Nov 8. Erratum in: J Pharmacol Exp Ther. 2013 May;345(2):327. Nishimura, Toshiko [corrected to Nishimura, Toshihiko].

2.

Chimeric mice with humanized liver.

Katoh M, Tateno C, Yoshizato K, Yokoi T.

Toxicology. 2008 Apr 3;246(1):9-17. doi: 10.1016/j.tox.2007.11.012. Epub 2007 Nov 22. Review.

PMID:
18248870
3.

Effect of hepatitis C virus infection on the mRNA expression of drug transporters and cytochrome p450 enzymes in chimeric mice with humanized liver.

Kikuchi R, McCown M, Olson P, Tateno C, Morikawa Y, Katoh Y, Bourdet DL, Monshouwer M, Fretland AJ.

Drug Metab Dispos. 2010 Nov;38(11):1954-61. doi: 10.1124/dmd.109.031732. Epub 2010 Aug 6.

4.

Use of transgenic mouse models to understand the oral disposition and drug-drug interaction potential of cobimetinib, a MEK inhibitor.

Choo EF, Woolsey S, DeMent K, Ly J, Messick K, Qin A, Takahashi R.

Drug Metab Dispos. 2015 Jun;43(6):864-9. doi: 10.1124/dmd.115.063743. Epub 2015 Mar 26.

5.

Preclinical Pharmacokinetics and In Vitro Metabolism of Asunaprevir (BMS-650032), a Potent Hepatitis C Virus NS3 Protease Inhibitor.

Mosure KW, Knipe JO, Browning M, Arora V, Shu YZ, Phillip T, Mcphee F, Scola P, Balakrishnan A, Soars MG, Santone K, Sinz M.

J Pharm Sci. 2015 Sep;104(9):2813-23. doi: 10.1002/jps.24356. Epub 2015 Jan 28.

PMID:
25631585
6.

In vivo induction of human cytochrome P450 3A4 by rifabutin in chimeric mice with humanized liver.

Katoh M, Watanabe M, Tabata T, Sato Y, Nakajima M, Nishimura M, Naito S, Tateno C, Iwasaki K, Yoshizato K, Yokoi T.

Xenobiotica. 2005 Sep;35(9):863-75.

PMID:
16308281
7.

Application of chimeric mice with humanized liver for predictive ADME.

Katoh M, Yokoi T.

Drug Metab Rev. 2007;39(1):145-57. Review.

PMID:
17364883
8.

Maraviroc: in vitro assessment of drug-drug interaction potential.

Hyland R, Dickins M, Collins C, Jones H, Jones B.

Br J Clin Pharmacol. 2008 Oct;66(4):498-507. doi: 10.1111/j.1365-2125.2008.03198.x. Epub 2008 Apr 10.

9.

Evaluation of Time Dependent Inhibition Assays for Marketed Oncology Drugs: Comparison of Human Hepatocytes and Liver Microsomes in the Presence and Absence of Human Plasma.

Mao J, Tay S, Khojasteh CS, Chen Y, Hop CE, Kenny JR.

Pharm Res. 2016 May;33(5):1204-19. doi: 10.1007/s11095-016-1865-9. Epub 2016 Feb 11.

PMID:
26869174
10.

In vitro phase I cytochrome P450 metabolism, permeability and pharmacokinetics of SB639, a novel histone deacetylase inhibitor in preclinical species.

Venkatesh PR, Goh E, Zeng P, New LS, Xin L, Pasha MK, Sangthongpitag K, Yeo P, Kantharaj E.

Biol Pharm Bull. 2007 May;30(5):1021-4.

11.

Casopitant: in vitro data and SimCyp simulation to predict in vivo metabolic interactions involving cytochrome P450 3A4.

Motta P, Pons N, Pagliarusco S, Pellegatti M, Bonomo F.

Drug Metab Dispos. 2011 Mar;39(3):363-72. doi: 10.1124/dmd.110.035071. Epub 2010 Dec 13.

12.

Non-invasive method to detect induction of CYP3A4 in chimeric mice with a humanized liver.

Emoto C, Yamato Y, Sato Y, Ohshita H, Katoh M, Tateno C, Yokoi T, Yoshizato K, Iwasaki K.

Xenobiotica. 2008 Mar;38(3):239-48. doi: 10.1080/00498250701760159 .

PMID:
18274954
13.

Inhibition and stimulation of intestinal and hepatic CYP3A activity: studies in humanized CYP3A4 transgenic mice using triazolam.

van Waterschoot RA, Rooswinkel RW, Sparidans RW, van Herwaarden AE, Beijnen JH, Schinkel AH.

Drug Metab Dispos. 2009 Dec;37(12):2305-13. doi: 10.1124/dmd.109.029397. Epub 2009 Sep 14.

14.

2'-deoxy-4'-azido nucleoside analogs are highly potent inhibitors of hepatitis C virus replication despite the lack of 2'-alpha-hydroxyl groups.

Klumpp K, Kalayanov G, Ma H, Le Pogam S, Leveque V, Jiang WR, Inocencio N, De Witte A, Rajyaguru S, Tai E, Chanda S, Irwin MR, Sund C, Winqist A, Maltseva T, Eriksson S, Usova E, Smith M, Alker A, Najera I, Cammack N, Martin JA, Johansson NG, Smith DB.

J Biol Chem. 2008 Jan 25;283(4):2167-75. Epub 2007 Nov 14.

15.

Prediction of human drug-drug interactions from time-dependent inactivation of CYP3A4 in primary hepatocytes using a population-based simulator.

Xu L, Chen Y, Pan Y, Skiles GL, Shou M.

Drug Metab Dispos. 2009 Dec;37(12):2330-9. doi: 10.1124/dmd.108.025494. Epub 2009 Sep 22.

16.

Assessment of chimeric mice with humanized liver as a tool for predicting circulating human metabolites.

Kamimura H, Nakada N, Suzuki K, Mera A, Souda K, Murakami Y, Tanaka K, Iwatsubo T, Kawamura A, Usui T.

Drug Metab Pharmacokinet. 2010;25(3):223-35. Review.

17.

Application of chimeric mice with humanized liver for study of human-specific drug metabolism.

Bateman TJ, Reddy VG, Kakuni M, Morikawa Y, Kumar S.

Drug Metab Dispos. 2014 Jun;42(6):1055-65. doi: 10.1124/dmd.114.056978. Epub 2014 Apr 3.

18.
19.

CYP2C9-catalyzed metabolism of S-warfarin to 7-hydroxywarfarin in vivo and in vitro in chimeric mice with humanized liver.

Inoue T, Nitta K, Sugihara K, Horie T, Kitamura S, Ohta S.

Drug Metab Dispos. 2008 Dec;36(12):2429-33. doi: 10.1124/dmd.108.022830. Epub 2008 Sep 10.

20.

Evaluation of P450 inhibition and induction by artemisinin antimalarials in human liver microsomes and primary human hepatocytes.

Xing J, Kirby BJ, Whittington D, Wan Y, Goodlett DR.

Drug Metab Dispos. 2012 Sep;40(9):1757-64. doi: 10.1124/dmd.112.045765. Epub 2012 Jun 7.

Supplemental Content

Support Center